☆ 4.7 Review

Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Induced by Natural Infection or Vaccination: A Systematic Review and Pooled Analysis

CLINICAL INFECTIOUS DISEASES (2022)

Related references

Note: Only part of the references are listed.

Article Immunology

Comparison of Four SARS-CoV-2 Neutralization Assays

Lydia Riepler et al.

Summary: Neutralizing antibodies are crucial for protection against viruses like SARS-CoV-2. This study compared four different assays for detecting these antibodies and found that they were all robust and yielded comparable results, indicating their reliability.

VACCINES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

Piyada Supasa et al.

Summary: Research on the UK-dominant variant B.1.1.7 shows that it is harder to neutralize than the parental virus, but widespread escape from antibodies or monoclonal antibodies has not been observed yet.

CELL (2021)

Add to Collection

Article Microbiology

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies

Allison J. Greaney et al.

Summary: The evolution of SARS-CoV-2 may impact the recognition of the virus by human antibody-mediated immunity, with mutations affecting antibody binding varying significantly among individuals and within the same individual over time. Despite this variability, mutations that greatly reduce antibody binding usually occur at specific sites in the RBD, with E484 being the most crucial. These findings can inform surveillance efforts for SARS-CoV-2 evolution in the future.

CELL HOST & MICROBE (2021)

Add to Collection

Article Multidisciplinary Sciences

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Pengfei Wang et al.

Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.

NATURE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

Rita E. Chen et al.

Summary: The study analyzed antibody neutralization activity against a panel of authentic isolates and chimeric SARS-CoV-2 variants, showing significantly reduced neutralizing activity against the B.1.351 variant first identified in South Africa. Antibodies targeting the receptor-binding domain and N-terminal domain, monoclonal antibodies, convalescent sera, and mRNA vaccine-induced immune sera exhibited decreased inhibitory activity against viruses with an E484K spike mutation, suggesting a need for updated monoclonal antibodies or vaccine adjustments to prevent loss of protection against emerging variants.

NATURE MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Neutralizing Activity of BNT162b2-Elicited Serum

Yang Liu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Eric J. Haas et al.

Summary: This study assessed the real-world effectiveness of the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 in Israel, showing high efficacy in preventing SARS-CoV-2 infections, hospitalizations, severe disease, and death. As vaccine coverage increased, there were marked declines in SARS-CoV-2 outcomes, indicating that COVID-19 vaccination can help control the pandemic.

LANCET (2021)

Add to Collection

Article Multidisciplinary Sciences

Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England

Erik Volz et al.

Summary: Genetic and testing data from England indicate that the SARS-CoV-2 variant B.1.1.7 has a transmission advantage over other lineages, showing a rapid expansion during autumn 2020. Analysis of S gene target failures (SGTF) in community-based diagnostic PCR testing suggests that B.1.1.7 is more transmissible than non-variant of concern lineages and has a significant transmission advantage, with a reproduction number 50% to 100% higher. Additionally, cases of B.1.1.7 appear to include a larger share of under 20-year-olds compared to non-variant cases.

NATURE (2021)

Add to Collection

Letter Medicine, General & Internal

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

Laith J. Abu-Raddad et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization

Guo-Lin Wang et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

S. A. Madhi et al.

Summary: The ChAdOx1 nCoV-19 vaccine did not provide significant protection against mild-to-moderate Covid-19 caused by the B.1.351 variant, with an efficacy of 10.4%. The incidence of serious adverse events was balanced between the vaccine and placebo groups.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Infectious Diseases

Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel

Yaniv Lustig et al.

Summary: The study found that healthcare workers vaccinated with Comirnaty showed reduced neutralising titres against the Gamma, Beta, and Delta variants, but the remaining neutralisation capacity may still be protective.

EUROSURVEILLANCE (2021)

Add to Collection

Letter Biochemistry & Molecular Biology

SARS-CoV-2 variants of concern are emerging in India

Jasdeep Singh et al.

NATURE MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Immune response to SARS-CoV-2 variants of concern in vaccinated individuals

Matthias Becker et al.

Summary: This study characterizes the antibody response from vaccinated, infected, and uninfected individuals against emerging variants of concern of SARS-CoV-2, indicating reduced neutralization of a South African isolate. High IgG titers in the saliva of vaccinees suggest reduced transmission potential.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Cell Biology

Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals

Alison Tarke et al.

Summary: The study showed that SARS-CoV-2 variants do not significantly disrupt total T cell reactivity, although decreases in response frequency of 10%-22% were observed under certain assay/VOC combinations. This underscores the importance of actively monitoring T cell responses in the context of SARS-CoV-2 evolution.

CELL REPORTS MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

A new coronavirus associated with human respiratory disease in China

Fan Wu et al.

NATURE (2020)

Add to Collection

Article Microbiology

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

Andrew Rambaut et al.

NATURE MICROBIOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Thomas F. Rogers et al.

SCIENCE (2020)

Add to Collection

Article Biology

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Yiska Weisblum et al.

ELIFE (2020)

Add to Collection

Review Microbiology

The spike protein of SARS-CoV - a target for vaccine and therapeutic development

Lanying Du et al.

NATURE REVIEWS MICROBIOLOGY (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.